Quick answer
Economic Survey 2025-26 places India third in pharma volume but eleventh in export value; ₹4.72 lakh crore turnover in FY25 highlights scope for innovation-led upgrading.
Pharmaceutical manufacturing produces medicines and their active ingredients, while medical-device manufacturing supplies diagnostic and therapeutic equipment. India’s strength in affordable generics must increasingly be complemented by complex products, research and resilient upstream supplies.
Concept diagram
Pharmaceutical Industry: Exports and Policy
A pharmaceutical lab traces starting materials through APIs to finished medicines, backed by research and quality.
- APIs are active ingredients, not finished medicine formulations.
- Input resilience and regulatory quality underpin export competitiveness.
Decode the pharmaceutical value chain
API, KSM and formulation
- An Active Pharmaceutical Ingredient supplies the medicine’s therapeutic action. Key Starting Materials and Drug Intermediates feed its production; formulations turn active ingredients into usable medicines.
Generics and biosimilars
- Generics provide equivalents of reference small-molecule medicines. Biosimilars are highly similar to approved biological medicines; their complexity makes them different from simple chemical copies.
Volume versus value
- A high number of doses need not yield a proportionately high export value. Complex generics, biosimilars and innovative medicines can create greater value than competing only on low-cost volume.
Pharma and devices: strengths with headroom
| Indicator | Survey finding |
|---|---|
| Global position | Third-largest pharmaceutical industry by volume; 11th in pharma exports by value, with a 3% share |
| Generic medicines | Approximately 20% of global generics demand supplied |
| FY25 turnover | ₹4.72 lakh crore |
| Pharmaceutical market reach | Exports to 191 countries in FY25; over 50% directed to highly regulated markets such as the US and Europe |
| Medical devices | Exports to 187 countries; US$2.5 billion in FY21 to US$4.1 billion in FY25 |
| Pharma export trajectory | 7% CAGR over FY15–FY25 |
Data chart
Pharmaceutical exports: selected decade endpoints
- Exports roughly double across the decade.
- The Survey reports 7% CAGR; chart-read points should not be used to claim greater precision.
Source: Economic Survey 2025-26, Chart VIII.17 (DGCI&S) · Values read from the Survey chart; approximate. Selected years only; figures cover the categories stated in the original chart.
Show the data (US$ billion)
| Period / item | Bulk drugs, intermediates, formulations and biologicals |
|---|---|
| FY15 | 14.8 |
| FY20 | 19.9 |
| FY25 | 29.1 |
Box VIII.3: resilience and standards instruments
| Policy | Evidence / function |
|---|---|
| PLI for Bulk Drugs | ₹4,763 crore investment by September 2025; capacity of 55,000 MT/year for 26 critical products |
| Fermentation-based production | Penicillin G Potassium is a precursor for several semi-synthetic antibiotics; local processes reduce upstream vulnerability |
| SPI / RPTUAS | ₹500 crore SPI outlay; 255 technology-upgradation applications approved to help meet global standards |
| Bulk Drug Parks | Three parks in Gujarat, Himachal Pradesh and Andhra Pradesh; ₹3,000 crore total outlay |
| PLI for Medical Devices | ₹1,093.69 crore actual investment by September 2025; manufacturing of 57 high-end devices started |
| Medical Devices Parks | ₹100 crore financial assistance each approved for Uttar Pradesh, Tamil Nadu and Madhya Pradesh; land allotted to 184 manufacturers |
| SMDI | Launched November 2024; ₹500 crore outlay for import-dependence reduction, capacity building and clinical studies |
Move from affordable scale to higher value
Secure upstream inputs
Build critical API and intermediate capacity, with common park infrastructure and environmental facilities.
Upgrade quality and technology
Help smaller units meet standards; apply advanced manufacturing, AI and 3D printing where appropriate in devices.
Win regulated markets
Invest in complex products and streamline global certification to combine market access with reliable quality.
Pharma rankings and park locations: frequent errors
Statements examiners like to twist — learn the correct version.
Third by volume means third in export value.
The Survey gives 11th place in pharmaceutical export value, not third.
All drug exports are APIs.
Exports include bulk drugs, intermediates, formulations and biologicals.
Bulk Drug Parks and Medical Devices Parks have identical beneficiary states.
The drug parks are in Gujarat, Himachal Pradesh and Andhra Pradesh; the cited device-park assistance is for Uttar Pradesh, Tamil Nadu and Madhya Pradesh.
Prelims focus
- Recall API, KSM, DI, biosimilar and generic distinctions.
- Memorise the different state groups for bulk drugs and medical devices.
Mains angle
- Discuss how India can reconcile affordable medicine supply with innovation-led pharmaceutical upgrading.
- Link upstream resilience, environmental common facilities and regulatory compliance in an industrial-policy answer.
Flip & recall
Answer in your head first, then tap the card to check.
Practice MCQs
Original Prelims-style questions with explanations.
0 / 3 correct · 3 left
Q1.Which pair is correctly matched?
Q2.The therapeutic action of a medicine is supplied by its:
Q3.The Survey’s value-upgrading strategy emphasises:
